title: Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.
abstract: The diagnostic value of elevated human chorionic gonadotropin (hCG) and its free alpha (hCG alpha) and beta (hCG beta) subunit serum levels as specific tumor markers for nongonadal malignancies is controversial. In the present report, different monoclonal based immunoradiometric assays specific for hCG and its free hCG alpha and hCG beta subunits have been used to reevaluate the presence of these molecules in the serum of patients with a wide variety of tumors. Serum samples from patients with newly diagnosed, persistent, or recurrent malignancies of either known (n = 717) or unknown (n = 32) primary site, healthy blood donors (n = 309), and nonmalignant disease controls (n = 86) were studied using four highly specific and sensitive monoclonal based immunoradiometric assays to hCG and its free subunits. Low level hCG elevations (less than 1000 pg/ml) were found to be common in cancer patients, normal subjects, and disease controls. However, serum levels greater than 1000 pg/ml were highly diagnostic of gonadal tumors and specifically identified nonseminomatous testicular tumors. Significant serum elevations of free hCG alpha subunit (as high as 3000 pg/ml) were found in approximately 96% of cancer patients, normal individuals, and disease controls. In contrast, free hCG beta subunit levels (greater than or equal to 100 pg/ml) were detected in 70 and 50% of patients with nonseminomatous and seminomatous testicular cancers, respectively, and in 47% of bladder, 32% of pancreatic, and 30% of cervical carcinomas. All normal subjects and disease controls had free hCG beta levels less than 100 pg/ml. Thus, the detection of the free hCG beta subunit in serum of nonpregnant subjects was highly diagnostic of malignancy in general and specifically defines a subgroup of aggressive nongonadal malignancies.
authors.affiliation: Department of Molecular Immunology, Institut G. Roussy, Villejuif, France.
authors.forename: I
authors.initials: I
authors.lastname: Marcillac
authors.forename: F
authors.initials: F
authors.lastname: Troalen
authors.forename: J M
authors.initials: JM
authors.lastname: Bidart
authors.forename: P
authors.initials: P
authors.lastname: Ghillani
authors.forename: V
authors.initials: V
authors.lastname: Ribrag
authors.forename: B
authors.initials: B
authors.lastname: Escudier
authors.forename: B
authors.initials: B
authors.lastname: Malassagne
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
authors.forename: C
authors.initials: C
authors.lastname: Lhommé
authors.forename: P
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood* / Q000737:chemistry; D006063:Chorionic Gonadotropin / Q000097:blood* / Q000737:chemistry; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D015292:Glycoprotein Hormones, alpha Subunit / Q000097:blood*; D006801:Humans; D015592:Immunoradiometric Assay / Q000379:methods; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis; D010446:Peptide Fragments / Q000097:blood* / Q000737:chemistry
chemical_list: D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D015292:Glycoprotein Hormones, alpha Subunit; D010446:Peptide Fragments